Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
November 7, 2025 · via Europe PMC
Mid-Term Results of an Unsupported Body Fenestrated Graft for Treating Thoracoabdominal and Suprarenal Aneurysms.
Oliny A, Bordet M, Ammollo RP, Arsicot M, Della Schiava N, Millon A.
AI summary — for doctors, generated from the abstract only
A specific type of fenestrated stent-graft (Anaconda) for treating complex aortic aneurysms near the kidneys and chest achieved acceptable mid-term survival and good target vessel patency, though nearly 30% of patients required a repeat procedure.
What was studied
A retrospective study of 57 patients electively treated with the Anaconda Fenestrated endograft for thoracoabdominal (TAA, n=25) or suprarenal (SRAA, n=32) aortic aneurysms at a single center (2018-2023), assessing survival, technical success, target-vessel patency, reintervention, and endoleaks over a mean follow-up of about 2.5 years.
Key findings
- Technical success was 94.7%, with 3 early deaths (5.3%), 1 case of permanent paraplegia, and 1 type IIIc endoleak, for an early clinical success rate of 93.0%.
- Overall survival was 87.7% at 1 year and 78.1% at 4 years (12 total deaths, 4 aneurysm-related); target vessel patency was 95.9% at 1 year and 95.2% at 5 years.
- 17 of 57 patients (29.8%) required early or late reintervention, with freedom from reintervention of 76.1% at 1 year and 61.1% at 3 years.
- Aneurysm sac shrinkage (a sign of successful treatment) occurred in 55.8% of patients, while growth occurred in only 3.8%.
Clinical relevance
The findings suggest that this fenestrated stent-graft is an acceptable treatment option for complex aortic aneurysms, with good mid-term survival and target vessel patency, but the authors note the notable reintervention rate (about 30%) warrants caution and ongoing surveillance for patients treated with this device.
Who should care
Limitations
Single-center retrospective study (57 patients) without a direct comparison group using alternative fenestrated devices, which limits ability to determine whether this device performs better or worse than established platforms; the authors themselves call for larger studies with longer follow-up.
A fenestrated endograft for complex aortic aneurysms achieved 78% survival at 4 years with good vessel patency, though nearly 30% of patients needed a repeat procedure during follow-up.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Purpose
To evaluate the safety and efficacy of a strategy using the Anaconda Fenestrated endograft for treating thoracoabdominal aortic aneurysms (TAA) and supra-renal aortic aneurysms (SRAAs).
Methods
Patients electively treated with the Anaconda Fenestrated endograft for an unruptured TAA or SRAA at our center between 2018 and 2023 were retrospectively analyzed. The treatment strategy included staged procedures prior to fenestrated endovascular aneurysm repair (FEVAR) and implantation of the Anaconda graft into thoracic grafts for TAA and for SRAA with an unfavorable proximal landing zone. Primary outcome was survival. Secondary outcomes included technical and early clinical success, target-vessel patency (TVP), freedom from reintervention, sac evolution, target-vessel instability (TVI), and endoleaks.
Results
A total of 57 patients (72% male, median age 70 years) were included, comprising 32 (56.1%) SRAA and 25 (43.9%) TAA. Nineteen patients (33.3%) underwent staged procedures, and technical success was 94.7%. There were 3 (5.3%) early deaths, 1 (1.8%) permanent paraplegia, and 1 (1.8%) type IIIc endoleak, leading to an early clinical success rate of 93.0%. The mean follow-up duration was 31.6 ± 19.7 months for mortality, and 28 ± 17.0 months for other outcomes. A total of 12 (21.1%) deaths were recorded, including 4 aneurysm-related deaths, resulting in 1-year and 4-year overall survival rates of 87.7% and 78.1%, respectively. The primary TVP rate was 95.9% at 1 year and 95.2% at 5 years, while the 1-year and 3-year freedom from TVI was 84.7% and 72.2%, respectively. Seventeen patients (29.8%) required early (n=7) or late (n=14) reinterventions, resulting in 1-year and 3-year freedom from reintervention of 76.1% and 61.1%, respectively. One type 1a (1.8%), 1 type 1b (1.8%), and 5 type 3c (8.8%) endoleaks were identified and treated during follow-up. Aneurysm growth (>5 mm) was observed in 2 patients (3.8%), while sac shrinkage (>5 mm) was achieved in 29 patients (55.8%).
Conclusion
This study demonstrates that a strategy using the Anaconda Fenestrated endograft provides acceptable efficacy and safety in the treatment of SRAA and TAA. Despite a high reintervention rate, mid-term survival, and target-vessel patency support the use of this endograft as a valid treatment option for these aneurysms.Clinical ImpactThis study reports the outcomes of 57 patients treated for suprarenal and thoracoabdominal aneurysms using the Anaconda unsupported fenestrated stent graft, combined with thoracic modules when necessary. Mid-term survival and target vessel patency were acceptable, with no indication of inferior performance compared to established platforms. While the reintervention rate warrants caution, these findings support the Anaconda fenestrated system as a potential alternative for complex aneurysms. Larger studies with extended follow-up are needed to better identify patients who may benefit from an unsupported design and to confirm its long-term durability.
DOI
10.1177/15266028251388017
PMID
41200827
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed